• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 11-K filed by Edwards Lifesciences Corporation

    6/17/25 4:29:24 PM ET
    $EW
    Industrial Specialties
    Health Care
    Get the next $EW alert in real time by email
    11-K 1 ew11-k2024puertoricoplan.htm 11-K Document

    Table of Contents

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
     
    WASHINGTON, D.C. 20549
     
     
    FORM 11-K
     
    (Mark One)
    ý    ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
     
    For the fiscal year ended December 31, 2024
     
    OR
     
    o    TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
     
    For the transition period from                to               
     
    Commission file number 1-15525

     
    A.             Full title of the plan and the address of the plan, if different from that of the issuer named below:
     
    Edwards Lifesciences (Puerto Rico) Corporation
    Retirement Savings Plan
     
    B.               Name of issuer of the securities held pursuant to the plan and the address of its principal executive office:
     
    Edwards Lifesciences Corporation
     
    One Edwards Way
    Irvine, California 92614
    (949) 250-2500





    Table of Contents
    Edwards Lifesciences (Puerto Rico) Corporation
    Retirement Savings Plan
    Index to Financial Statements and Supplemental Schedules
     
     Page
    Reports of Independent Registered Public Accounting Firms
    1
    Financial Statements:
     
    Statements of Net Assets Available for Benefits as of December 31, 2024 and 2023
    3
    Statements of Changes in Net Assets Available for Benefits for the years ended December 31, 2024 and 2023
    4
    Notes to Financial Statements
    5
    Supplementary Information
    Schedule H, Line 4a - Schedule of Delinquent Participant Contributions
    11
    Schedule H, Line 4i - Schedule of Assets (Held at End of Year)
    12
    Signature
    13
    Exhibits:
     
    23.1—Consent of Independent Registered Public Accounting Firm
    23.2—Consent of Independent Registered Public Accounting Firm 




    Table of Contents
    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


    The Administrative and Investment Committee and Plan Participants
    Edwards Lifesciences (Puerto Rico) Corporation Retirement Savings Plan

    Opinion on the Financial Statements

    We have audited the accompanying statement of net assets available for benefits of the Edwards Lifesciences (Puerto Rico) Corporation Retirement Savings Plan (the “Plan”) as of December 31, 2024, the related statement of changes in net assets available for benefits for the year then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2024, and the changes in net assets available for benefits for the year then ended in conformity with accounting principles generally accepted in the United States of America.

    Basis for Opinion

    These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

    We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plan is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Plan’s internal control over financial reporting. Accordingly, we express no such opinion.

    Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures to respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

    Opinion on the Supplementary Information

    The supplementary information included in Schedule H, Line 4(a) - Schedule of Delinquent Participant Contributions for the year ended December 31, 2024 and the Schedule H, Line 4(i) - Schedule of Assets (Held at End of Year) as of December 31, 2024, have been subjected to audit procedures performed in conjunction with the audit of the Plan’s financial statements. The supplementary information are the responsibility of the Plan's management. Our audit procedures included determining whether the supplementary information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplementary information. In forming our opinion on the supplementary information in the accompanying schedules, we evaluated whether the supplementary information, including their form and content, are presented in conformity with the Department of Labor's Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act. In our opinion, the supplementary information in the accompanying schedules are fairly stated, in all material respects, in relation to the financial statements as a whole.

     
    /s/ BDO USA, P.C. 
    Costa Mesa, California
     
    June 17, 2025 

    We have served as the Plan's auditor since 2025.
    1


    Table of Contents
    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


    The Administrative and Investment Committee and Plan Participants
    Edwards Lifesciences (Puerto Rico) Corporation Retirement Savings Plan (formerly, the Edwards Lifesciences Technology SARL Retirement Savings Plan)

    Opinion on the Financial Statements

    We have audited the accompanying statement of net assets available for benefits of the Edwards Lifesciences (Puerto Rico) Corporation Retirement Savings Plan (formerly, the Edwards Lifesciences Technology SARL Retirement Savings Plan) (the Plan) as of December 31, 2023, the related statement of changes in net assets available for benefits for the year then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2023, and the changes in net assets available for benefits for the year then ended in conformity with accounting principles generally accepted in the United States of America.

    Basis for Opinion

    The financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

    We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plan is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Plan’s internal control over financial reporting. Accordingly, we express no such opinion.

    Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures to respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.


    /s/ Moss Adams LLP 
    San Francisco, California 
    June 20, 2024 

    We have served as the Plan’s auditor from 2018 to 2024.
    2


    Table of Contents

    Edwards Lifesciences (Puerto Rico) Corporation
    Retirement Savings Plan
    Statements of Net Assets Available for Benefits
     
     
     December 31,
     20242023
    Plan's interest in Master Trust at fair value (Note 4)
    $31,254,979 $43,970,505 
    Notes receivable from participants163,485 868,008 
    Dividends and interest receivable— 2 
    Contributions receivable8,084 125,261 
    NET ASSETS AVAILABLE FOR BENEFITS$31,426,548 $44,963,776 
     
     
     
    The accompanying notes are an integral part of these financial statements.

    3


    Table of Contents
    Edwards Lifesciences (Puerto Rico) Corporation
    Retirement Savings Plan
    Statements of Changes in Net Assets Available for Benefits
     
     
     Years Ended December 31,
     20242023
    Additions to net assets attributed to:
      
    Plan's interest in Master Trust net investment income (Note 2)
    $3,201,255 $4,623,621 
    Interest income on notes receivable from participants50,349 46,731 
    Contributions:
    Participant contributions1,802,508 2,254,656 
    Company contributions, net of forfeitures895,954 1,357,826 
    Rollover contributions73,360 — 
    Total contributions2,771,822 3,612,482 
    Total additions6,023,426 8,282,834 
    Deductions from net assets attributed to:
    Benefits paid to participants (Note 1)
    19,396,648 3,529,951 
    Administrative expenses164,006 131,500 
    Total deductions19,560,654 3,661,451 
    Net (decrease) increase in net assets available for benefits(13,537,228)4,621,383 
    Net assets available for benefits:
    Beginning of year44,963,776 40,342,393 
    End of year$31,426,548 $44,963,776 
     
     
     
    The accompanying notes are an integral part of these financial statements.

    4


    Table of Contents
    Edwards Lifesciences (Puerto Rico) Corporation
    Retirement Savings Plan
    Notes to Financial Statements
     
     
    1.                 Description of the Plan
     
    The following description of the Edwards Lifesciences (Puerto Rico) Corporation Retirement Savings Plan (the “Plan”) is provided for general information purposes only. Participants should refer to the Plan document for more complete information.

    General

    The Plan is a defined contribution retirement plan subject to the provisions of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”). Participation in the Plan is available to employees of Edwards Lifesciences (Puerto Rico) Corporation (the “Company” or "Edwards") who have met certain eligibility requirements, as described below.

    On September 3, 2024, the Company sold its Critical Care product group ("Critical Care") to Becton, Dickinson and Company ("BD"). Effective August 29, 2024, the Plan was amended and restated to change the sponsorship of the Plan to Edwards Lifesciences (Puerto Rico) Corporation (formerly, Edwards Lifesciences Technology SARL) and the name of the Plan to Edwards Lifesciences (Puerto Rico) Corporation Retirement Savings Plan (formerly, the Edwards Lifesciences Technology SARL Retirement Savings Plan). Participants impacted by the sale had their unvested Company matching fully vested and had the option to (1) rollover their vested balances to BD's plan, (2) receive a distribution of their balance as described in the Payment of Benefits section below, or (3) leave their account balances in the Plan. Those participants with outstanding loans under the Plan were required to rollover their balances to BD's plan for the loans to remain active. If the participant chose not to rollover their balances to BD's plan, the participant was required to repay any outstanding loans in accordance with the Plan regulations.

    Eligibility

    All regular, nonunion employees receiving compensation sourced in the Commonwealth of Puerto Rico are eligible to participate in the Plan on the thirty-first day after an employee is credited with an hour of service, unless the employee is otherwise not eligible for participation under the Plan.

    Plan Administration

    The Plan is administered by the Administrative and Investment Committee for the Edwards Lifesciences Corporation Employee Benefit Plans (the “Committee”). The Committee has authority, responsibility, and control over the management of the assets of the Plan. Members of the Committee are appointed by the Board of Directors of Edwards Lifesciences Corporation (“Parent Company”) and are employees of the Parent Company. Banco Popular de Puerto Rico (“Trustee”) serves as the trustee of the Plan, Voya Institutional Trust Company serves as the Plan’s custodian, and Voya Institutional Plan Services, LLC provides record keeping services for the Plan.

    Contributions

    The Plan allows tax deferred contributions intended to qualify under the applicable laws of the Commonwealth of Puerto Rico. Eligible participants may make pre-tax contributions up to 25% of their eligible annual compensation within certain limitations. The Company matches the first 4% of the participant’s annual eligible compensation contributed to the Plan at the rate of 50 cents for each contributed dollar. In addition, if a participant is age 50 or older, the participant is allowed to make additional catch-up contributions within certain Puerto Rico code limitations.

    Additionally, each eligible employee, regardless of whether they contribute to the Plan, receives a profit sharing contribution in an amount targeted at 2% of such employee’s Retirement Savings Plan eligible earnings for the prior year as defined by the Plan. Certain employees are also eligible for a supplemental contribution related to changes in the Company’s prior pension plan.

    The Plan has an automatic enrollment feature whereby eligible employees are automatically enrolled in the Plan at a pre-tax contribution rate of 3% of eligible pay. Participant contribution rates are automatically increased by 1% each year thereafter
    5


    Table of Contents
    until they reach 5% of eligible pay. Employees may opt out of the automatic enrollment, stop contributions, or modify their contribution rate at any time.

    Participant Accounts

    Each participant’s account is credited with the participant’s contributions, the Company’s matching and profit sharing contributions, and the allocation of the participant’s share of the Plan’s net earnings and losses, net of certain investment management fees and administrative expenses. Allocations are based on participant account balances, as defined.

    Vesting

    Participants are immediately fully vested in their Plan accounts (other than their Company matching and profit sharing contributions), plus actual earnings thereon. Vesting in a participant’s Company matching and profit sharing contributions plus actual earnings thereon is based on years of continuous service. Participants are vested 100% in Company matching and profit sharing contributions after three years of credited service. Participants are immediately fully vested in any supplemental profit sharing contributions received as a result of the changes in the Company's prior year pension plan. Upon termination of service due to death, disability, or attainment of normal retirement age, a participant shall become fully vested.

    Notes Receivable from Participants

    Participants may borrow an amount ranging from a minimum of $1,000 up to a maximum equal to the lesser of $50,000 or 50% of their vested account balances. The notes bear interest based on the applicable prime rate at the time of issuance plus 1%, and have a maximum term of five years (or ten years if used to acquire a home). The loans are collateralized by the participants’ vested interest in their accounts and any additional collateral as the Committee may require. Principal and interest are generally paid ratably through payroll deductions.

    Payment of Benefits

    Upon termination of service or otherwise becoming eligible to receive benefits, a participant may elect to (1) receive a lump-sum amount equal to the value of the participant’s vested account, (2) receive periodic installments, or (3) transfer the balance in the participant’s vested account to another qualified plan. Vested accounts of $1,000 or less will be automatically paid in a lump-sum amount.

    A participant may make withdrawals from the participant’s vested accounts (except as provided in the Plan document) if the participant is over age 59 ½, is fully vested, and has completed five years of Plan participation. Withdrawals may also be made for financial hardship, which is determined pursuant to the provisions of the Puerto Rico Internal Revenue Code.

    Administrative Expenses

    Substantially all costs and expenses incurred in the administration of the Plan are paid from the assets of the Plan.

    Forfeitures

    A participant’s non-vested balance is forfeited at the time of termination of employment. Such forfeitures may be used to offset future Company matching contributions. Forfeitures of $10,165 were used to offset Company matching contributions during 2024. No forfeitures were used to offset Company contributions during 2023. Forfeitures outstanding were $47,229 and $12,800 as of December 31, 2024 and 2023, respectively.
     
    2.                 Summary of Significant Accounting Policies
     
    Basis of Accounting
     
    The accompanying financial statements of the Plan have been prepared on the accrual basis of accounting in conformity with accounting principles generally accepted in the United States of America.
     
    Investment Valuation and Income Recognition

    The Plan’s investment in the Master Trust (see Note 4) is recorded at the net asset value ("NAV") of the underlying investments within the Master Trust. The Master Trust’s assets are primarily invested in funds managed by the Trustee through
    6


    Table of Contents
    a commingled employee benefit funds trust. Units have been purchased in funds which invest primarily in securities of major U.S. companies, international equity securities in both developed and emerging markets, and government agency fixed income securities. These investments are stated at fair value.

    Purchases and sales of securities are recorded by the Master Trust on a trade-date basis. Realized gains and losses for security transactions are reported using the average cost method. Net appreciation (depreciation) in the Master Trust includes realized gains and losses on the sale of investments, and unrealized appreciation or depreciation. Interest and dividend income are recorded on an accrual basis, and dividends are recorded on the ex-dividend date.
     
    Notes Receivable from Participants
     
    Notes receivable from participants are measured at their unpaid principal balance plus accrued interest. Delinquent participant loans are classified as deemed as distributions based upon the terms of the Plan document.
     
    Contributions

    Employee and employer contributions are recorded in the period in which the employee contributions are withheld from compensation.

    Payment of Benefits
     
    Benefits to participants are recorded when paid.
     
    Use of Estimates
     
    The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and related notes to the financial statements. Changes in such estimates may affect amounts reported in future periods.

    Risks and Uncertainties
     
    The Plan provides for various investment options in any combination of investment securities. Investment securities are exposed to various risks, such as interest rate, market, and credit. Due to the level of risk associated with certain investment securities and the level of uncertainty related to changes in the value of investment securities, it is at least reasonably possible that changes in risks in the near term would materially affect participants’ account balances and the amounts reported in the Statements of Net Assets Available for Benefits and the Statements of Changes in Net Assets Available for Benefits.
     
    The Plan’s share of the Stable Value Fund, a common collective trust fund, invests in a variety of investment contracts such as guaranteed investment contracts, bank investment contracts, and a wrapped portfolio of fixed income instruments. Certain events may limit the ability of the Plan to transact at contract value with the issuer. The Plan administrator does not believe that the occurrence of any such event is probable.

    3.                 Fair Value Measurements
     
    Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. The Company prioritizes the inputs used to determine fair values in one of the following three categories:
     
    Level 1 – Quoted market prices in active markets for identical assets or liabilities.
    Level 2 – Inputs, other than quoted prices in active markets, that are observable, either directly or indirectly.
    Level 3 – Unobservable inputs that are not corroborated by market data.
     
    In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety.
     
    7


    Table of Contents
    The following table summarizes the Master Trust’s financial instruments which are measured at fair value on a recurring basis as of December 31, 2024 and 2023:
     
    December 31, 2024
    Level 1Level 2Level 3Total
    Common stock$351,300,340 $— $— $351,300,340 
    Mutual funds670,027,278 — — 670,027,278 
    U.S. government and other debt securities1,177,794 98,784 — 1,276,578 
    Certificates of deposit— 1,369,214 — 1,369,214 
    Money market fund
    1,413,173 — — 1,413,173 
    Subtotal$1,023,918,585 $1,467,998 $— 1,025,386,583 
    Cash
    5,988,656 
    Common/collective trust funds measured at NAV (a)877,940,044 
    Total (b)
    $1,909,315,283 

    December 31, 2023
    Level 1Level 2Level 3Total
    Common stock$378,058,101 $— $— $378,058,101 
    Mutual funds546,379,659 — — 546,379,659 
    U.S. government and other debt securities1,013,685 265,072 — 1,278,757 
    Certificates of deposit— 511,442 — 511,442 
    Subtotal$925,451,445 $776,514 $— 926,227,959 
    Cash and money market funds6,877,256 
    Common/collective trust funds measured at NAV (a)757,489,676 
    Total (b)
    $1,690,594,891 
    _______________________________________
    (a)     In accordance with ASC Subtopic 820-10, certain investments that were measured at NAV per share as a practical expedient have not been classified in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the line items presented in the statement of net assets available for benefits.

    (b)    The Plan's interests within the Master Trust (see Note 4) are leveled in the same manner as the Master Trust investment categories presented above.

    Common stock, mutual fund, and money market investments are valued at fair value based on quoted market prices reported on the active markets on which the individual securities are traded, and are categorized as Level 1 

    U.S. government and other debt securities are valued at fair value based on quoted market prices, where available. If a quoted market price is not available, the fair value is determined using pricing models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, including reported trades and broker-dealer quotes on the same or similar securities, benchmark yields, credit spreads, prepayment and default projections based on historical data, and other observable inputs.

    Certificates of deposit are measured at amortized cost, which approximates fair value, and are categorized as Level 2.

    Cash consists of monies on deposit for transactions pending settlement.

    Common/collective trust funds and money market funds are valued using the NAV provided by the administrator of the fund. The NAV is based on the fair value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. As of December 31, 2024, there were no unfunded commitments related to common/collective trust funds or money market funds. Investments in these funds can be redeemed by participants daily and, in general, do not have a redemption notification period. However, the Plan may be required to provide a one-year redemption notice to fully or partially liquidate its share in the funds. It is not probable that investments in these funds would be sold at amounts that differ materially from the NAV of the units held.
    8


    Table of Contents
     
    During the years ended December 31, 2024 and 2023, there were no transfers in or out of Levels 1 or 2 of the fair value hierarchy.
     
    4.                 Investments
     
    The Master Trust, administered by Voya Institutional Trust Company, holds the assets of the Plan and the Edwards Lifesciences Corporation 401(k) Savings and Investment Plan.
     
    The accompanying Statements of Net Assets Available for Benefits reflect the apportioned share of the underlying Plan assets and liabilities of the Trust. Allocations of net investment income from the Trust are based on the Plan’s net assets at the beginning of the year with adjustments for contributions and benefit payments made during the year.

    Summarized financial information for the Trust as of December 31, 2024 and 2023 is as follows:
     
     Master TrustPlan's Interest in Master Trust
     2024202320242023
    Net assets held by Master Trust:  
    Common stock
    $351,300,340 $378,058,101 $4,103,115 $7,246,196 
    Mutual funds670,027,278 546,379,659 21,903,242 25,475,883 
    U.S. government and other debt securities1,276,578 1,278,757 — — 
    Common/collective trusts877,940,044 757,489,676 5,248,622 11,248,422 
    Certificates of deposit1,369,214 511,442 — — 
    Cash and money market funds7,401,829 6,877,256 — 4 
    Net assets held by Master Trust 1,909,315,283 1,690,594,891 31,254,979 43,970,505 
    Plus:
    Accrued interest and dividends2,940 5,618 — 2 
    Total$1,909,318,223 $1,690,600,509 $31,254,979 $43,970,507 
     
    Net investment income from the Master Trust's investments for the years ended December 31, 2024 and 2023 is as follows:
     
     Years Ended December 31,
     20242023
    Net appreciation in fair value
    $157,419,254 $173,383,756 
    Dividend income 26,490,763 20,792,757 
    Interest income 12,341,399 7,292,546 
    Net investment income from the Master Trust
    $196,251,416 $201,469,059 
      
    5.                 Distribution Priorities upon Termination of the Plan
     
    Although it has not expressed any intent to do so, the Company has the right under the Plan to reduce, suspend, or discontinue its contributions at any time and to terminate the Plan subject to the provisions of ERISA. Upon termination of the Plan, the account balance of each participant will become 100% vested and all assets, net of expenses, will be distributed to the participants or the participants’ beneficiaries.
     
    6.                 Tax Status of the Plan
     
    The Company has received a favorable determination letter from the Puerto Rico Treasury Department (“Departmento de Hacienda”) on the Plan’s Puerto Rico qualified status for income tax purposes. Although the Plan has since been amended, the Plan Administrator believes the Plan’s design and operation are in compliance with the applicable provisions and requirements of the Puerto Rico Internal Revenue Code and, therefore, believes that the Plan is qualified and the related trust is tax exempt.
    9


    Table of Contents
     
    Accounting principles generally accepted in the United States require the Plan’s management to evaluate tax positions taken by the Plan and recognize a tax liability (or asset) if the Plan has taken an uncertain position that more likely than not would not be sustained upon examination by the Puerto Rico Treasury Department. The Plan Administrator has analyzed the tax positions taken by the Plan and has concluded that as of December 31, 2024, there are no uncertain positions taken or expected to be taken that would require recognition of a liability (or asset) or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions. 

    7.                 Exempt Party-in-Interest Transactions
     
    Parties-in-interest are defined under the Department of Labor regulations as any fiduciary of the Plan, any party rendering service to the Plan, an employer whose employees are covered by the Plan, and certain others. At December 31, 2024 and 2023, the Plan, through its investment in the Master Trust, held shares of common stock of the Parent Company, as follows:
     
     20242023
    Shares of Edwards Lifesciences stock held by Plan55,425 95,029 
    Value of Edwards Lifesciences stock held by Plan$4,103,093 $7,245,929 
    Plan’s investment in Edwards Lifesciences stock as percentage of total net assets available for benefits
    13.1 %16.1 %

    Plan assets include loans to participants. These transactions are allowable party-in-interest transactions under ERISA and the regulations promulgated thereunder.
     
    8.                 Reconciliation of Financial Statements to Form 5500
     
    The following is a reconciliation of amounts reported in the financial statements to amounts reported on Form 5500 as of and for the years ended December 31, 2024 and 2023:
     20242023
    Statement of Net Assets Available for Benefits:  
    Net assets available for benefits per the financial statements$31,426,548 $44,963,776 
    Deemed distributions
    (67,641)(57,585)
    Net assets available for benefits per Form 5500$31,358,907 $44,906,191 

     20242023
    Statement of Changes in Net Assets Available for Benefits:  
    Net (decrease) increase in net assets available for benefits per the financial statements
    $(13,537,228)$4,621,383 
    Changes in deemed distributions
    (10,056)(1,103)
    Net (loss) income per Form 5500
    $(13,547,284)$4,620,280 

    9. Delinquent Participant Contributions

    Certain participant contributions totaling $3,040 related to the 2023 Plan tax year were not remitted to the Plan within the timeframe prescribed by the Department of Labor. This was deemed to be a prohibited transaction in accordance with ERISA. The Company corrected the prohibited transaction during 2024.
    10


    Table of Contents


    Edwards Lifesciences (Puerto Rico) Corporation
    Retirement Savings Plan
    EIN: 66-0579279, Plan #: 002
    Schedule H – line 4a – Schedule of Delinquent Participant Contributions
    As of December 31, 2024
     
    Participant Contributions Transferred Late to PlanTotal that Constitute Nonexempt Prohibited Transactions
    Year
    Check Here if Late Participant Loan Repayments are Included: o
    Contributions Not Corrected
    Contributions Corrected Outside VFCP1
    Contributions Pending Corrections in VFCP1
    Total Fully Corrected Under VFCP1 and PTE2 2002-51
    2023$3,040 $— $3,040 $— $— 
    1                 Voluntary Fiduciary Correction Program
    2             Prohibited Transaction Exemption
    11


    Table of Contents
    Edwards Lifesciences (Puerto Rico) Corporation
    Retirement Savings Plan
    EIN: 66-0579279, Plan #: 002
    Schedule H – line 4i – Schedule of Assets (Held at End of Year)
    As of December 31, 2024
     
    (a) (b) Identity of issue,
    borrower, lessor
    or similar party
     (c) Description of investment including maturity date, rate
    of interest, collateral, par or maturity value
     (d) Cost
    **
     (e) Current
    value
    * Notes Receivable from Participants 
    Varying maturity dates with interest rates ranging from of 4.25% to 9.5%
     — $163,485 
     

    *                    Party-in-interest for which a statutory exemption exists.
     
    **             Cost information is not required for participant-directed investments and, therefore, has not been included in this schedule.

    12


    Table of Contents
    SIGNATURE
     
    The Plan. Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the administrator of the Plan has duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     EDWARDS LIFESCIENCES (PUERTO RICO) CORPORATION
    RETIREMENT SAVINGS PLAN
      
    June 17, 2025By:/s/ CHRISTINE Z. MCCAULEY
      Christine Z. McCauley
      Member of the Administrative and
    Investment Committee for the
    Edwards Lifesciences Corporation
    Employee Benefit Plans

    13


    Table of Contents
    EXHIBIT INDEX
     
     
    Exhibit No. Description
    23.1 
    Consent of Independent Registered Public Accounting Firm
    23.2
    Consent of Independent Registered Public Accounting Firm


    Get the next $EW alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $EW

    DatePrice TargetRatingAnalyst
    4/24/2025$80.00Neutral → Overweight
    Piper Sandler
    1/30/2025$75.00 → $90.00Hold → Buy
    Stifel
    1/16/2025$60.00Peer Perform → Underperform
    Wolfe Research
    12/16/2024Neutral → Buy
    BofA Securities
    10/11/2024$70.00Equal-Weight
    Morgan Stanley
    9/18/2024$85.00 → $70.00Buy → Hold
    Jefferies
    7/31/2024Neutral → Outperform
    Daiwa Securities
    7/29/2024Underperform → Peer Perform
    Wolfe Research
    More analyst ratings

    $EW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CVP, EMEACLA Bruls Annette covered exercise/tax liability with 109 shares, decreasing direct ownership by 0.76% to 14,171 units (SEC Form 4)

      4 - Edwards Lifesciences Corp (0001099800) (Issuer)

      7/11/25 5:43:52 PM ET
      $EW
      Industrial Specialties
      Health Care
    • CVP, JAPAC Lippis Daniel J. covered exercise/tax liability with 333 shares, decreasing direct ownership by 1% to 26,116 units (SEC Form 4)

      4 - Edwards Lifesciences Corp (0001099800) (Issuer)

      7/7/25 5:40:40 PM ET
      $EW
      Industrial Specialties
      Health Care
    • Global President TAVR & Surg Wood Larry L exercised 8,950 shares at a strike of $59.26 and sold $673,268 worth of shares (8,950 units at $75.23) (SEC Form 4)

      4 - Edwards Lifesciences Corp (0001099800) (Issuer)

      6/16/25 5:09:27 PM ET
      $EW
      Industrial Specialties
      Health Care

    $EW
    SEC Filings

    See more
    • SEC Form 11-K filed by Edwards Lifesciences Corporation

      11-K - Edwards Lifesciences Corp (0001099800) (Filer)

      6/17/25 4:29:24 PM ET
      $EW
      Industrial Specialties
      Health Care
    • SEC Form 11-K filed by Edwards Lifesciences Corporation

      11-K - Edwards Lifesciences Corp (0001099800) (Filer)

      6/17/25 4:28:40 PM ET
      $EW
      Industrial Specialties
      Health Care
    • SEC Form SD filed by Edwards Lifesciences Corporation

      SD - Edwards Lifesciences Corp (0001099800) (Filer)

      5/30/25 4:27:10 PM ET
      $EW
      Industrial Specialties
      Health Care

    $EW
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NYSE Content Advisory: Pre-Market update + Wall Street watches the Middle East

      NEW YORK, June 24, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.  Kristen Scholer delivers the pre-market update on June 24th Equities are rising Tuesday morning as traders closely monitor the latest developments in the Middle East. On Monday, the major averages rose by close to 1% amid the region's ongoing conflict.At approximately 6 PM ET yesterday evening, President Donald Trump announced on Truth Social that a ceasefire agreement has been reached between Israel and Iran. However, Israel and Iran l

      6/24/25 8:55:00 AM ET
      $EW
      $ICE
      Industrial Specialties
      Health Care
      Investment Bankers/Brokers/Service
      Finance
    • Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes

      Edwards Lifesciences (NYSE:EW) today announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025, further contributing to the extensive body of research on this disease. The results of a new real-world study of more than 24,000 patients demonstrated that intervening on the disease before symptoms develop reduces the economic and resource burden on the healthcare system and improves patient outcomes. Prompt intervention for severe AS patients before symptoms developed resulted in: Significantly lower costs for the healthcare system at 1 year ($36,000 less per patient); Shorter length of stay during their treatm

      5/22/25 2:30:00 AM ET
      $EW
      Industrial Specialties
      Health Care
    • Edwards Lifesciences to Present at the BofA Securities 2025 Health Care Conference

      Edwards Lifesciences (NYSE:EW) today announced it will participate in the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, will participate in a fireside chat at 10:40 a.m. Pacific Time. A live webcast of the discussion will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and p

      5/6/25 7:05:00 AM ET
      $EW
      Industrial Specialties
      Health Care

    $EW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Zovighian Bernard J covered exercise/tax liability with 4,245 shares, converted options into 6,265 shares and bought $49,753 worth of shares (580 units at $85.74), increasing direct ownership by 5% to 46,836 units (SEC Form 4)

      4 - Edwards Lifesciences Corp (0001099800) (Issuer)

      5/7/24 5:53:27 PM ET
      $EW
      Industrial Specialties
      Health Care

    $EW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Edwards Lifesciences upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Edwards Lifesciences from Neutral to Overweight and set a new price target of $80.00

      4/24/25 7:18:16 AM ET
      $EW
      Industrial Specialties
      Health Care
    • Edwards Lifesciences upgraded by Stifel with a new price target

      Stifel upgraded Edwards Lifesciences from Hold to Buy and set a new price target of $90.00 from $75.00 previously

      1/30/25 7:10:09 AM ET
      $EW
      Industrial Specialties
      Health Care
    • Edwards Lifesciences downgraded by Wolfe Research with a new price target

      Wolfe Research downgraded Edwards Lifesciences from Peer Perform to Underperform and set a new price target of $60.00

      1/16/25 7:43:13 AM ET
      $EW
      Industrial Specialties
      Health Care

    $EW
    Leadership Updates

    Live Leadership Updates

    See more
    • Scaling its Investment Platform in Minimally Invasive Care, Intuitive Ventures Appoints Terri Burke as Senior Partner and Ross Jaffe as Venture Advisor

      Intuitive Ventures today announced the appointment of Terri Burke, former head medtech investments at Epidarex Capital and a seasoned operator, as Senior Partner and Dr. Ross Jaffe, a co-founder of Versant Ventures, as Venture Advisor. Both medtech veterans, they will help support the continued growth of Intuitive Ventures in investing in start-ups reimagining the future of minimally invasive care. With more than two decades of medtech investing and operational leadership experience, Burke will help support the growth of the firm's investment platform. With over $250 million in assets under management, Intuitive Ventures invests in founders tackling large, meaningful problems that positive

      3/6/25 8:00:00 AM ET
      $EW
      Industrial Specialties
      Health Care
    • EDWARDS LIFESCIENCES ANNOUNCES CEO SUCCESSION PLAN

      IRVINE, Calif., Dec. 8, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE:EW) today announced that following regular succession planning discussions with the Board of Directors, Edwards' chairman and CEO, Michael A. Mussallem, who recently turned 70, has informed the Board of his decision to retire as CEO in connection with the company's Annual Meeting of Stockholders on May 11, 2023. At the 2023 annual meeting, Mussallem will stand for election as non-executive chairman of Edwards' Board. He will be succeeded as CEO by Bernard Zovighian, currently corporate vice pre

      12/8/22 8:00:00 AM ET
      $EW
      Industrial Specialties
      Health Care
    • Edwards Announces Updates From Annual Meeting

      IRVINE, Calif., May 5, 2021 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE:EW) today announced updates from its annual meeting, in which Edwards' stockholders voted with the board's recommendations on all proxy proposals: All eight director nominees were elected as directors of the company for a one-year term; Stockholders advised that they approve the compensation of the company's named executive officers; Stockholders have approved the Amendment and Restatement of the company's U.S. and International Employee Stock Purchase Plans; Stockholders have ratified the appoi

      5/5/21 9:15:00 AM ET
      $EW
      Industrial Specialties
      Health Care

    $EW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Edwards Lifesciences Corporation

      SC 13G - Edwards Lifesciences Corp (0001099800) (Subject)

      11/8/24 10:34:33 AM ET
      $EW
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Edwards Lifesciences Corporation

      SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)

      10/4/24 2:14:28 PM ET
      $EW
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Edwards Lifesciences Corporation (Amendment)

      SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)

      2/13/24 5:04:42 PM ET
      $EW
      Industrial Specialties
      Health Care

    $EW
    Financials

    Live finance-specific insights

    See more
    • Edwards Lifesciences Reports First Quarter Results

      Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended Mar. 31, 2025. Recent Highlights Q1 sales grew 6.2% to $1.41 billion, or 7.9% adjusted1 Q1 TAVR sales grew 3.8%; constant currency1 sales grew 5.4%, better than expected Q1 TMTT sales grew 58% to $115 million with meaningful contribution to Edwards' growth Q1 EPS of $0.622; adjusted1 EPS of $0.64 SAPIEN M3 CE Mark approval uniquely positions Edwards with a comprehensive TMTT portfolio NCD finalized for transcatheter tricuspid valve replacement, expanding patient access to EVOQUE Multiple TAVR studies presented at ACC confirm the need for urgent patient referral to Heart Team Data from Hear

      4/23/25 4:15:00 PM ET
      $EW
      Industrial Specialties
      Health Care
    • Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025

      Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended March 31, 2025 after the market closes on Wednesday April 23, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and

      4/16/25 7:05:00 AM ET
      $EW
      Industrial Specialties
      Health Care
    • Edwards Lifesciences Reports Fourth Quarter Results

      Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024. Highlights and Outlook Q4 sales grew 9% to $1.39 billion1, better than expected, with strength across all product groups Q4 TAVR sales grew 6%; constant currency2 sales grew 5% Q4 TMTT sales grew 88% to $105 million with increasing contribution to Edwards' growth Q4 EPS of $0.581; adjusted2 EPS of $0.59, driven by strong top-line performance Presented results of two practice-changing FDA clinical trials, EARLY TAVR and TRISCEND II Reiterating 2025 constant currency sales growth of 8% - 10%; adjusted EPS of $2.40 - $2.50 Continuing to expect mid-year asymp

      2/11/25 4:15:00 PM ET
      $EW
      Industrial Specialties
      Health Care